LBPH (Longboard Pharmaceuticals, Inc.) Business Value to Revenue

Public company logo of Longboard Pharmaceuticals, Inc. (LBPH)

The continuity of research at Longboard Pharmaceuticals (LBPH) relies on diversified raw material supply chains, while the EV/Sales valuation ratio on the GURU.Markets daily chart shows that indicates the current level. Risks are mitigated by strict FDA oversight and colossal R&D expenditures, while a stable cash flow is ensured by the lifelong treatment of patients with severe forms of epilepsy.

LBPH - Longboard EV/Sales Multiple over the range 07/04/2022 - 11/20/2026

LBPH (Longboard Pharma): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- business market valuation indicators:
Initial company analysis:Longboard Pharmaceuticals
Mass-produced product of Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals (LBPH) minimizes capital expenditures by outsourcing production and testing to third-party contractors to maintain a strategic focus on neurobiology. By analyzing the enterprise value-to-revenue multiple, an investor assesses the market value of the business relative to its sales regardless of debt load, which allows for the determination of the efficiency of the company's intellectual asset capitalization through the lens of this chart.

Competitor analysis for Longboard Pharmaceuticals

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|KTTA: Company Value to Revenue|Business Value to Revenue CRGT (cortigent.com)|ATXI: EV/Sales Multiple|BCLI (BrainStorm Cell Therapeutics) - Enterprise Value-to-Revenue Ratio|CARA (Cara Therapeutics Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio CHRO|Company Value to Revenue ELYM (Eliem Therapeutics)|Enterprise Value-to-Revenue Ratio ITCI (Intra-Cellular Therapies Inc.)|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE